

Oncology Molecular Diagnostics Market - Global Outlook & Forecast 2023-2028

Market Report | 2023-12-06 | 365 pages | Arizton Advisory & Intelligence

AVAILABLE LICENSES:

- Single User License \$4200.00
- Team License \$4999.00
- Enterprisewide \$5999.00

Report description:

The global oncology molecular diagnostics market is expected to grow at a CAGR of 14.81% from 2022-2028.

MARKET TRENDS & DRIVERS

Growing Significance of Companion Diagnostics for Oncology Drug Development

Companion diagnostics have become paramount in oncology drug development, aligning treatment decisions with patient-specific molecular profiles. These tests enable identifying individuals likely to respond to targeted therapies while excluding non-responders, enhancing treatment efficacy. As pharmaceutical companies increasingly integrate companion diagnostics into their drug development pipelines, precision medicine becomes a cornerstone of oncology, offering more effective and personalized treatment options for cancer patients. This growing significance of companion diagnostics is revolutionizing how oncology drugs are developed and administered, ultimately improving patient outcomes.

Increasing Partnerships & Collaboration for the Development of Oncology Molecular Diagnostics

Increasingly, partnerships and collaborations are shaping the landscape of oncology molecular diagnostics. Diagnostic companies, pharmaceutical firms, and research institutions are joining forces to develop cutting-edge molecular tests and companion diagnostics. These collaborations aim to accelerate the translation of genomic discoveries into clinical applications, enhancing the precision of cancer diagnosis and treatment and ultimately improving patient outcomes in the rapidly evolving field of oncology molecular diagnostics.

Emerging Immuno-oncology Based Cancer Treatments

Emerging immuno-oncology-based cancer treatments represent a prominent global oncology molecular diagnostics market trend. These therapies harness the body's immune system to combat cancer cells, emphasizing precision medicine. Molecular diagnostics are pivotal in identifying biomarkers for patient selection, monitoring treatment response, and developing innovative

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

immuno-oncology therapies. This trend promises to revolutionize cancer care, offering more effective and personalized treatment options.

Rising Global Cancer Prevalence

The rising global cancer prevalence is a significant driver of the market. As cancer cases increase worldwide due to factors such as aging populations and lifestyle changes, there is a growing need for accurate and early cancer detection. Oncology molecular diagnostics play a crucial role in diagnosing and monitoring cancer, guiding treatment decisions, and ultimately improving patient outcomes in the face of this escalating global health challenge.

Transformation of Precision Cancer Care

The transformation of precision cancer care, driven by advances in molecular diagnostics, is a major catalyst for the growth of the oncology molecular diagnostics market. With a focus on tailoring treatments to individual genetic profiles, this paradigm shift enhances treatment efficacy, reduces side effects, and drives the demand for advanced diagnostic technologies in oncology. As oncologists increasingly rely on molecular insights to make informed treatment decisions, the market continues to expand to meet the growing need for personalized cancer care.

New Product Launches

New product launches are pivotal in driving the oncology molecular diagnostics market. These innovations continually expand the repertoire of diagnostic tools and solutions, enhancing molecular tests' accuracy, sensitivity, and clinical utility. By introducing novel assays, platforms, and technologies, new product launches empower healthcare providers to make more informed treatment decisions and improve patient outcomes in the ever-evolving field of oncology molecular diagnostics.

Technological Advancements in Molecular Diagnostics

Technological advancements in molecular diagnostics, including NGS, PCR techniques, and high-throughput platforms, are driving the oncology molecular diagnostics market. These innovations enable more accurate and comprehensive profiling of genetic and molecular alterations in cancer, facilitating personalized treatment strategies and early detection, ultimately improving patient outcomes and fueling market growth.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT TYPE

The global oncology molecular diagnostics market by product type is segmented into kits & reagents and instruments & platforms. The kits & reagents accounted for the market share in the product type segment in 2022 and is expected to grow at the highest CAGR during the forecast period. The kits & reagents are essential components of molecular diagnostics. They include DNA/RNA extraction kits, PCR reagents, nucleotide probes, and sequencing reagents. These products are vital for preparing and analyzing biological samples for cancer-specific biomarkers. Further, the instruments & platform category comprises various laboratory equipment and analytical instruments for molecular diagnostics, including PCR machines, NGS platforms, microarray scanners, and automated liquid handling systems. These instruments enable the processing and analysis of genetic and molecular data. Molecular diagnostic software is crucial in data analysis, interpretation, and reporting. It includes bioinformatics tools, data management software, and specialized algorithms for genomic analysis.

Segmentation by Product Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Kits & Reagents
- Instruments & Platforms

INSIGHTS BY CANCER TYPE

The global oncology molecular diagnostics market by cancer type is segmented into breast, colorectal, lung, and blood. In 2022, breast cancer dominated the global market share. Molecular diagnostics are crucial in breast cancer prognosis and treatment selection, identifying hormone receptor status (ER, PR) and HER2/neu amplification. Further, the colorectal cancer segment is expected to witness the highest segmental CAGR of over 15% during the forecast period. Colorectal cancer is a significant global health concern, accounting for millions of cancer-related deaths annually. Early detection and precise treatment are critical factors in improving patient outcomes.

Segmentation by Cancer Type

- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer
- Others

INSIGHTS BY TECHNOLOGY

The polymerase chain reaction (PCR) technology segment held the most prominent share of the global oncology molecular diagnostics market in 2022. PCR is a widely used technology that amplifies specific DNA sequences, allowing for the detection of genetic mutations and variations associated with various cancer types. It is known for its high sensitivity and specificity in identifying genetic abnormalities. The sequencing segment is expected to grow at the highest CAGR in the technology during the forecast period. The field of oncology has witnessed a transformative shift in how cancer is diagnosed, characterized, and treated, largely owing to advancements in molecular diagnostics. Sequencing technology has emerged as a powerful tool among the various techniques driving progress in this domain.

Segmentation by Technology

- Polymerase Chain Reaction (PCR)
- Hybridization
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Sequencing
- Other

INSIGHTS BY END-USER

The diagnostic laboratory end-user holds a dominant share of the global oncology molecular diagnostics market and is expected to witness the highest segmental CAGR during the forecast period. Diagnostic facilities perform molecular tests, including DNA and RNA analysis, to detect genetic mutations, biomarkers, and other cancer-related molecular alterations. Furthermore, hospital settings are significant consumers of molecular diagnostics in oncology. Oncology molecular diagnostics, encompassing various technologies such as DNA sequencing, PCR, and microarrays, have transformed cancer diagnosis, prognosis, and treatment decision-making. Hospitals are often the primary sites for diagnosing cancer. Oncology molecular diagnostics provide hospitals

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

with precise tools to identify the presence of cancer, classify its type, and determine its molecular characteristics.

Segmentation by End-user

- Diagnostic Laboratories
- Hospitals
- Other

GEOGRAPHICAL ANALYSIS

North America accounted for the highest global oncology molecular diagnostics market share in 2022, accounting for over 46%. The region boasts a robust healthcare infrastructure, including specialized cancer centers and research institutions. This supports the development, validation, and adoption of molecular diagnostics. The area is at the forefront of technology and innovation, driving the rapid growth of molecular diagnostic assays and platforms during the forecast. A significant number of clinical trials in oncology are conducted in North America, fostering the integration of molecular diagnostics into treatment decision-making. Well-defined regulatory processes, such as FDA approvals in the U.S., provide a clear pathway for market entry, boosting investor confidence.

Segmentation by Geography

- North America
 - o□The U.S.
 - o□Canada
- Europe
 - o□Germany
 - o□France
 - o□The U.K.
 - o□Italy
 - o□Spain
- APAC
 - o□China
 - o□Japan
 - o□India
 - o□South Korea
 - o□Australia
- Latin America
 - o□Brazil
 - o□Mexico
 - o□Argentina
- Middle East & Africa
 - o□Turkey
 - o□Saudi Arabia
 - o□South Africa

COMPETITIVE LANDSCAPE

The global oncology molecular diagnostics market is fiercely competitive, driven by an ever-increasing demand for accurate

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

cancer diagnosis and personalized treatment. The key players in the market, such as Abbott, Agilent Technologies, Danaher, F. Hoffmann-La Roche, QIAGEN, and Siemens Healthineers, among other prominent vendors, are driving the growth of oncology molecular diagnostics. Several vital strategies shape competition in the global oncology molecular diagnostics market. For instance, companies invest heavily in research and development to create more accurate and cost-effective diagnostic assays and technologies. This includes advancements in NGS, liquid biopsies, and companion diagnostics.

Key Company Profiles

- Abbott
- Agilent Technologies
- Danaher
- F.Hoffmann La-Roche
- QIAGEN
- Siemens Healthineers

Other Prominent Vendors

- BD
- BillionToOne
- Biocartis
- Biodesix
- bioMerieux
- Bio-Rad Laboratories
- Caris Life Sciences
- Epigenomics
- Exact Sciences
- Guardant Health
- Hologic
- Illumina
- Laboratory Corporation of America
- Lepu Medical Technology (Beijing)
- Myriad Genetics
- Sysmex Corporation
- Thermo Fisher Scientific

KEY QUESTIONS ANSWERED:

- 1.□How big is the oncology molecular diagnostics market?
- 2.□What is the growth rate of the global oncology molecular diagnostics market?
- 3.□Which region dominates the global oncology molecular diagnostics market share?
- 4.□What are the significant trends in the oncology molecular diagnostics market?
- 5.□Who are the key players in the global oncology molecular diagnostics market?

Table of Contents:

- 1 RESEARCH METHODOLOGY
- 2 RESEARCH OBJECTIVES
- 3 RESEARCH PROCESS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.3.1 MARKET SEGMENTATION BY PRODUCT TYPE

4.3.2 MARKET SEGMENTATION BY CANCER TYPE

4.3.3 MARKET SEGMENTATION BY TECHNOLOGY

4.3.4 MARKET SEGMENTATION BY END-USER

4.3.5 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 PREMIUM INSIGHTS

6.1 OVERVIEW

6.1.1 GEOGRAPHY INSIGHTS

6.1.2 PRODUCT TYPE INSIGHTS

6.1.3 CANCER TYPE INSIGHTS

6.1.4 TECHNOLOGY INSIGHTS

6.1.5 END-USER INSIGHTS

7 MARKET AT A GLANCE

8 INTRODUCTION

8.1 OVERVIEW

8.1.1 MOLECULAR DIAGNOSTICS IN ONCOLOGY

9 MARKET OPPORTUNITIES & TRENDS

9.1 GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS FOR ONCOLOGY DRUG DEVELOPMENT

9.2 INCREASING PARTNERSHIPS & COLLABORATION FOR DEVELOPMENT OF ONCOLOGY MOLECULAR DIAGNOSTICS

9.3 EMERGING IMMUNO-ONCOLOGY-BASED CANCER TREATMENTS

10 MARKET GROWTH ENABLERS

10.1 RISING GLOBAL CANCER PREVALENCE

10.2 TRANSFORMATION OF PRECISION CANCER CARE

10.3 NEW PRODUCT LAUNCHES

10.4 TECHNOLOGICAL ADVANCES IN MOLECULAR DIAGNOSTICS

11 MARKET RESTRAINTS

11.1 HIGH COST OF MOLECULAR DIAGNOSTICS TESTS

11.2 LACK OF SKILLED WORKFORCE & OPERATIONAL BARRIERS

11.3 AVAILABILITY OF ALTERNATIVE TECHNOLOGIES IN CANCER DIAGNOSIS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12 MARKET LANDSCAPE

12.1 MARKET OVERVIEW

12.2 MARKET SIZE & FORECAST

12.3 MARKET OPPORTUNITY

12.3.1 MARKET BY GEOGRAPHY

12.3.2 MARKET BY PRODUCT TYPE

12.3.3 MARKET BY CANCER TYPE

12.3.4 MARKET BY TECHNOLOGY

12.3.5 MARKET BY END-USER

12.4 FIVE FORCES ANALYSIS

12.4.1 THREAT OF NEW ENTRANTS

12.4.2 BARGAINING POWER OF SUPPLIERS

12.4.3 BARGAINING POWER OF BUYERS

12.4.4 THREAT OF SUBSTITUTES

12.4.5 COMPETITIVE RIVALRY

13 PRODUCT TYPE

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 KITS & REAGENTS

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.3.3 KITS & REAGENTS BY GEOGRAPHY

13.4 INSTRUMENTS & PLATFORMS

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.4.3 INSTRUMENTS & PLATFORM BY GEOGRAPHY

14 CANCER TYPE

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.3 BREAST CANCER

14.3.1 MARKET OVERVIEW

14.3.2 MARKET SIZE & FORECAST

14.3.3 BREAST CANCER BY GEOGRAPHY

14.4 COLORECTAL CANCER

14.4.1 MARKET OVERVIEW

14.4.2 MARKET SIZE & FORECAST

14.4.3 COLORECTAL CANCER BY GEOGRAPHY

14.5 LUNG CANCER

14.5.1 MARKET OVERVIEW

14.5.2 MARKET SIZE & FORECAST

14.5.3 LUNG CANCER BY GEOGRAPHY

14.6 BLOOD CANCER

14.6.1 MARKET OVERVIEW

14.6.2 MARKET SIZE & FORECAST

14.6.3 BLOOD CANCER BY GEOGRAPHY

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.7 OTHERS
 - 14.7.1 MARKET OVERVIEW
 - 14.7.2 MARKET SIZE & FORECAST
 - 14.7.3 OTHER BY GEOGRAPHY
- 15 TECHNOLOGY
 - 15.1 MARKET SNAPSHOT & GROWTH ENGINE
 - 15.2 MARKET OVERVIEW
 - 15.3 POLYMERASE CHAIN REACTION (PCR)
 - 15.3.1 MARKET OVERVIEW
 - 15.3.2 MARKET SIZE & FORECAST
 - 15.3.3 PCR BY GEOGRAPHY
 - 15.4 HYBRIDIZATION
 - 15.4.1 MARKET OVERVIEW
 - 15.4.2 MARKET SIZE & FORECAST
 - 15.4.3 HYBRIDIZATION BY GEOGRAPHY
 - 15.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
 - 15.5.1 MARKET OVERVIEW
 - 15.5.2 MARKET SIZE & FORECAST
 - 15.5.3 INAAT BY GEOGRAPHY
 - 15.6 SEQUENCING
 - 15.6.1 MARKET OVERVIEW
 - 15.6.2 MARKET SIZE & FORECAST
 - 15.6.3 SEQUENCING BY GEOGRAPHY
 - 15.7 OTHER
 - 15.7.1 MARKET OVERVIEW
 - 15.7.2 MARKET SIZE & FORECAST
 - 15.7.3 OTHER BY GEOGRAPHY
- 16 END-USER
 - 16.1 MARKET SNAPSHOT & GROWTH ENGINE
 - 16.2 MARKET OVERVIEW
 - 16.3 DIAGNOSTIC LABORATORIES
 - 16.3.1 MARKET OVERVIEW
 - 16.3.2 MARKET SIZE & FORECAST
 - 16.3.3 DIAGNOSTIC LABORATORIES BY GEOGRAPHY
 - 16.4 HOSPITALS
 - 16.4.1 MARKET OVERVIEW
 - 16.4.2 MARKET SIZE & FORECAST
 - 16.4.3 HOSPITALS BY GEOGRAPHY
 - 16.5 OTHER
 - 16.5.1 MARKET OVERVIEW
 - 16.5.2 MARKET SIZE & FORECAST
 - 16.5.3 OTHER BY GEOGRAPHY
- 17 GEOGRAPHY
 - 17.1 MARKET SNAPSHOT & GROWTH ENGINE

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.2 GEOGRAPHIC OVERVIEW

18 NORTH AMERICA

18.1 MARKET OVERVIEW

18.2 MARKET SIZE & FORECAST

18.2.1 NORTH AMERICA MARKET BY PRODUCT TYPE

18.2.2 NORTH AMERICA MARKET BY CANCER TYPE

18.2.3 NORTH AMERICA MARKET BY TECHNOLOGY

18.2.4 NORTH AMERICA MARKET BY END-USER

18.3 KEY COUNTRIES

18.3.1 US: MARKET SIZE & FORECAST

18.3.2 CANADA: MARKET SIZE & FORECAST

19 EUROPE

19.1 MARKET OVERVIEW

19.2 MARKET SIZE & FORECAST

19.2.1 EUROPE MARKET BY PRODUCT TYPE

19.2.2 EUROPE MARKET BY CANCER TYPE

19.2.3 EUROPE MARKET BY TECHNOLOGY

19.2.4 EUROPE MARKET BY END-USER

19.3 KEY COUNTRIES

19.3.1 GERMANY: MARKET SIZE & FORECAST

19.3.2 FRANCE: MARKET SIZE & FORECAST

19.3.3 UK: MARKET SIZE & FORECAST

19.3.4 ITALY: MARKET SIZE & FORECAST

19.3.5 SPAIN: MARKET SIZE & FORECAST

20 APAC

20.1 MARKET OVERVIEW

20.2 MARKET SIZE & FORECAST

20.2.1 APAC MARKET BY PRODUCT TYPE

20.2.2 APAC MARKET BY CANCER TYPE

20.2.3 APAC MARKET BY TECHNOLOGY

20.2.4 APAC MARKET BY END-USER

20.3 KEY COUNTRIES

20.3.1 CHINA: MARKET SIZE & FORECAST

20.3.2 JAPAN: MARKET SIZE & FORECAST

20.3.3 INDIA: MARKET SIZE & FORECAST

20.3.4 SOUTH KOREA: MARKET SIZE & FORECAST

20.3.5 AUSTRALIA: MARKET SIZE & FORECAST

21 LATIN AMERICA

21.1 MARKET OVERVIEW

21.2 MARKET SIZE & FORECAST

21.2.1 LATIN AMERICA MARKET BY PRODUCT TYPE

21.2.2 LATIN AMERICA MARKET BY CANCER TYPE

21.2.3 LATIN AMERICA MARKET BY TECHNOLOGY

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

21.2.4 LATIN AMERICA MARKET BY END-USER

21.3 KEY COUNTRIES

21.3.1 BRAZIL: MARKET SIZE & FORECAST

21.3.2 MEXICO: MARKET SIZE & FORECAST

21.3.3 ARGENTINA: MARKET SIZE & FORECAST

22 MIDDLE EAST & AFRICA

22.1 MARKET OVERVIEW

22.2 MARKET SIZE & FORECAST

22.2.1 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE

22.2.2 MIDDLE EAST & AFRICA MARKET BY CANCER TYPE

22.2.3 MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY

22.2.4 MIDDLE EAST & AFRICA MARKET BY END-USER

22.3 KEY COUNTRIES

22.3.1 TURKEY: MARKET SIZE & FORECAST

22.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST

22.3.3 SOUTH AFRICA: MARKET SIZE & FORECAST

23 COMPETITIVE LANDSCAPE

23.1 COMPETITION OVERVIEW

23.2 MARKET SHARE ANALYSIS

23.2.1 ABBOTT

23.2.2 AGILENT TECHNOLOGIES

23.2.3 DANAHER

23.2.4 F. HOFFMANN LA-ROCHE

23.2.5 QIAGEN

23.2.6 SIEMENS HEALTHINEERS

24 KEY COMPANY PROFILES

24.1 ABBOTT

24.1.1 BUSINESS OVERVIEW

24.1.2 PRODUCT OFFERINGS

24.1.3 KEY STRATEGIES

24.1.4 KEY STRENGTHS

24.1.5 KEY OPPORTUNITIES

24.2 AGILENT TECHNOLOGIES

24.2.1 BUSINESS OVERVIEW

24.2.2 PRODUCT OFFERINGS

24.2.3 KEY STRATEGIES

24.2.4 KEY STRENGTHS

24.2.5 KEY OPPORTUNITIES

24.3 DANAHER

24.3.1 BUSINESS OVERVIEW

24.3.2 PRODUCT OFFERINGS

24.3.3 KEY STRATEGIES

24.3.4 KEY STRENGTHS

24.3.5 KEY OPPORTUNITIES

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 24.4 F. HOFFMANN-LA ROCHE
 - 24.4.1 BUSINESS OVERVIEW
 - 24.4.2 PRODUCT OFFERINGS
 - 24.4.3 KEY STRATEGIES
 - 24.4.4 KEY STRENGTHS
 - 24.4.5 KEY OPPORTUNITIES
- 24.5 QIAGEN
 - 24.5.1 BUSINESS OVERVIEW
 - 24.5.2 PRODUCT OFFERINGS
 - 24.5.3 KEY STRATEGIES
 - 24.5.4 KEY STRENGTHS
 - 24.5.5 KEY OPPORTUNITIES
- 24.6 SIEMENS HEALTHINEERS
 - 24.6.1 BUSINESS OVERVIEW
 - 24.6.2 PRODUCT OFFERINGS
 - 24.6.3 KEY STRATEGIES
 - 24.6.4 KEY STRENGTHS
 - 24.6.5 KEY OPPORTUNITIES

25 OTHER PROMINENT VENDORS

- 25.1 BD
 - 25.1.1 BUSINESS OVERVIEW
 - 25.1.2 PRODUCT OFFERINGS
- 25.2 BILLIONTOONE
 - 25.2.1 BUSINESS OVERVIEW
 - 25.2.2 PRODUCT OFFERINGS
- 25.3 BIOCARTIS
 - 25.3.1 BUSINESS OVERVIEW
 - 25.3.2 PRODUCT OFFERINGS
- 25.4 BIODESIX
 - 25.4.1 BUSINESS OVERVIEW
 - 25.4.2 PRODUCT OFFERINGS
- 25.5 BIOMERIEUX
 - 25.5.1 BUSINESS OVERVIEW
 - 25.5.2 PRODUCT OFFERINGS
- 25.6 BIO-RAD LABORATORIES
 - 25.6.1 BUSINESS OVERVIEW
 - 25.6.2 PRODUCT OFFERINGS
- 25.7 CARIS LIFE SCIENCES
 - 25.7.1 BUSINESS OVERVIEW
 - 25.7.2 PRODUCT OFFERINGS
- 25.8 EPIGENOMICS
 - 25.8.1 BUSINESS OVERVIEW
 - 25.8.2 PRODUCT OFFERINGS
- 25.9 EXACT SCIENCES
 - 25.9.1 BUSINESS OVERVIEW
 - 25.9.2 PRODUCT OFFERINGS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

25.10	GUARDANT HEALTH
25.10.1	BUSINESS OVERVIEW
25.10.2	PRODUCT OFFERINGS
25.11	HOLOGIC
25.11.1	BUSINESS OVERVIEW
25.11.2	PRODUCT OFFERINGS
25.12	ILLUMINA
25.12.1	BUSINESS OVERVIEW
25.12.2	PRODUCT OFFERINGS
25.13	LABORATORY CORPORATION OF AMERICA
25.13.1	BUSINESS OVERVIEW
25.13.2	PRODUCT OFFERINGS
25.14	LEPU MEDICAL TECHNOLOGY (BEIJING)
25.14.1	BUSINESS OVERVIEW
25.14.2	PRODUCT OFFERINGS
25.15	MYRIAD GENETICS
25.15.1	BUSINESS OVERVIEW
25.15.2	PRODUCT OFFERINGS
25.16	SYSMEX CORPORATION
25.16.1	BUSINESS OVERVIEW
25.16.2	PRODUCT OFFERINGS
25.17	THERMO FISHER SCIENTIFIC
25.17.1	BUSINESS OVERVIEW
25.17.2	PRODUCT OFFERINGS
26	REPORT SUMMARY
26.1	KEY TAKEAWAYS
26.2	STRATEGIC RECOMMENDATIONS
27	QUANTITATIVE SUMMARY
27.1	MARKET BY PRODUCT TYPE
27.1.1	NORTH AMERICA MARKET BY PRODUCT TYPE
27.1.2	EUROPE MARKET BY PRODUCT TYPE
27.1.3	APAC MARKET BY PRODUCT TYPE
27.1.4	LATIN AMERICA MARKET BY PRODUCT TYPE
27.1.5	MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
27.2	MARKET BY CANCER TYPE
27.2.1	NORTH AMERICA MARKET BY CANCER TYPE
27.2.2	EUROPE MARKET BY CANCER TYPE
27.2.3	APAC MARKET BY CANCER TYPE
27.2.4	LATIN AMERICA MARKET BY CANCER TYPE
27.2.5	MIDDLE EAST & AFRICA MARKET BY CANCER TYPE
27.3	MARKET BY TECHNOLOGY
27.3.1	NORTH AMERICA MARKET BY TECHNOLOGY
27.3.2	EUROPE MARKET BY TECHNOLOGY
27.3.3	APAC MARKET BY TECHNOLOGY
27.3.4	LATIN AMERICA MARKET BY TECHNOLOGY

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 27.3.5 MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY
- 27.4 MARKET BY END-USER
 - 27.4.1 NORTH AMERICA MARKET BY END-USER
 - 27.4.2 EUROPE MARKET BY END-USER
 - 27.4.3 APAC MARKET BY END-USER
 - 27.4.4 LATIN AMERICA MARKET BY END-USER
 - 27.4.5 MIDDLE EAST & AFRICA MARKET BY END-USER
- 27.5 MARKET BY GEOGRAPHY
 - 27.5.1 KITS & REAGENTS BY GEOGRAPHY
 - 27.5.2 INSTRUMENTS & PLATFORM BY GEOGRAPHY
 - 27.5.3 BREAST CANCER BY GEOGRAPHY
 - 27.5.4 COLORECTAL CANCER BY GEOGRAPHY
 - 27.5.5 LUNG CANCER BY GEOGRAPHY
 - 27.5.6 BLOOD CANCER BY GEOGRAPHY
 - 27.5.7 OTHER BY GEOGRAPHY
 - 27.5.8 PCR BY GEOGRAPHY
 - 27.5.9 HYBRIDIZATION BY GEOGRAPHY
 - 27.5.10 INAAT BY GEOGRAPHY
 - 27.5.11 SEQUENCING BY GEOGRAPHY
 - 27.5.12 OTHER BY GEOGRAPHY
 - 27.5.13 DIAGNOSTIC LABORATORIES BY GEOGRAPHY
 - 27.5.14 HOSPITALS BY GEOGRAPHY
 - 27.5.15 OTHER BY GEOGRAPHY

28 APPENDIX

28.1 ABBREVIATIONS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Oncology Molecular Diagnostics Market - Global Outlook & Forecast 2023-2028

Market Report | 2023-12-06 | 365 pages | Arizton Advisory & Intelligence

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4200.00
	Team License	\$4999.00
	Enterprisewide	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-24"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com